{"id":"NCT00812461","sponsor":"H. Lundbeck A/S","briefTitle":"Efficacy of Nalmefene in Patients With Alcohol Dependence","officialTitle":"Nalmefene Efficacy Study II: Randomised, Double-blind, Placebo-controlled, Parallel-group, Efficacy Study of 20 mg Nalmefene, as Needed Use, in Patients With Alcohol Dependence","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-03","primaryCompletion":"2011-03","completion":"2011-04","firstPosted":"2008-12-22","resultsPosted":"2013-07-09","lastUpdate":"2013-07-22"},"enrollment":678,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Alcohol Dependence"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Nalmefene","otherNames":["Selincroâ„¢"]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Nalmefene","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to evaluate the efficacy, safety and tolerability of nalmefene in the treatment of alcohol dependence.","primaryOutcome":{"measure":"Change From Baseline in the Monthly Number of Heavy Drinking Days (HDDs)","timeFrame":"Baseline and Month 6","effectByArm":[{"arm":"Placebo","deltaMin":-10.58,"sd":0.52},{"arm":"Nalmefene 18.06 mg","deltaMin":-12.3,"sd":0.54}],"pValues":[{"comp":"OG000 vs OG001","p":"0.012"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":7},"locations":{"siteCount":57,"countries":["Belgium","Czechia","France","Italy","Poland","Portugal","Spain"]},"refs":{"pmids":["23562264","25832297","25227627","23873853"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":337},"commonTop":["Nausea","Insomnia","Headache","Dizziness","Nasopharyngitis"]}}